Deals channel feed

MPP signs on four gener­ics mak­ers to make No­var­tis' Tasigna more ac­ces­si­ble

Last year
Pharma

As­traZeneca, Sanofi turn to Al­pha­bet spin­out's AI and quan­tum tech­nolo­gies for drug dis­cov­ery

Last year

Cor­rect­ed: Prime Med­i­cine part­ners with Ver­sant-backed biotech to de­vel­op safer stem cell trans­plants

Last year
Cell/Gene Tx

Aslan out­li­cens­es atopic der­mati­tis an­ti­body in $138.5M deal

Last year
R&D

Ae­glea Bio­Ther­a­peu­tics ac­quires start­up Spyre in bid to go af­ter Mer­ck’s Prometheus, Roivant’s Tela­vant

Last year
Financing
Startups

Tour­ma­line Bio re­verse merges in­to Ta­laris and rais­es funds to tar­get thy­roid eye dis­ease and phar­ma ri­vals

Last year
Financing
Startups

‘The sleep­ing gi­ant is wak­ing up’: FTC rais­es the pres­sure on phar­ma deal­mak­ing

Last year
Pharma
In Focus

De­spite a dip in M&A val­ue and vol­ume, PwC pre­dicts deal ac­tiv­i­ty to re­main strong with an uptick in IPOs

Last year

Swiss biotech un­loads US rights to Duchenne can­di­date for $231M

Last year

Lil­ly inks $2.4B cash deal to buy DICE and its im­munol­o­gy pipeline

Last year
R&D

Co­herus to buy Sur­face On­col­o­gy in stock deal val­ued at $65M

Last year
People

As­traZeneca en­lists an up­start Chi­na biotech part­ner in the wake of an R&D set­back

Last year
Bioregnum
China

Astel­las shells out $35M up­front to Cull­gen in pro­tein de­grad­er de­vel­op­ment deal

Last year

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Last year
Pharma
Cell/Gene Tx

Bio­gen lines up po­ten­tial deal for ALS drug, dou­bling down on neu­ro­fil­a­ment bio­mark­er

Last year

As­traZeneca amps en­vi­ron­men­tal goals with deal for re­new­able fu­el use at all US sites

Last year
Pharma
Marketing

Ery­tech blasts ac­tivist in­vestor's at­tempt to block re­verse merg­er, Akka­di­an pro­pos­es new board in re­turn

Last year
People

No­var­tis adds $3.2B cash deal to M&A tal­ly, snap­ping up Chi­nook and its late-stage kid­ney drugs

Last year
Pharma

Oslo biotech finds an­oth­er merg­er part­ner af­ter share­hold­ers re­ject­ed No­vem­ber of­fer

Last year
Financing

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Last year
Cell/Gene Tx

Q2 deal ac­tiv­i­ty points to po­ten­tial 'bumper year' for phar­ma — re­port

Last year
Pharma

Sam­sung Bi­o­log­ics se­cures $400M+ man­u­fac­tur­ing deal with Pfiz­er

Last year
Manufacturing

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Last year
R&D
Cell/Gene Tx

Deer­field taps NYU Lan­gone Health as lat­est aca­d­e­m­ic part­ner, ink­ing $130M trans­la­tion­al re­search pact

Last year
Discovery
First page Previous page 32333435363738 Next page Last page
A service from the Financial Times